LD-5 in sera from HC patients can be explained by the homotetrameric structure of LD-5, whose monomer, the so-called M subunit, is actively synthesized in hepatocytes, particularly during neoplastic transformation (14) . Why large amounts of LD-4 appear in SLN sera is obscure. The increase of LD-4 seen in sera from SLN patients cannot be attributed to high production of the isoenzyme by the primary tumor, because our AN patients without liver metastases did not show increased concentrations of LD-4. Moreover, clinical and laboratory data excluded the possibility that the enhanced LD-4 as well as LD-5 activity resulted from other diseases. Muscle damage was also excluded because creatine kinase activity in serum was within the reference values in all SLN and HO patients we examined.
(0.270 ± 0.047 moWL) and from hemodialyzed patients (0.214 ± 0.035 &moI/L). In serum of hemodiaiyzed patients, analyses for total MDA were unsuitable because of interfering peaks. MDAbound to NH2 groups constituted 83.2%and 83.5% of total MDAin serum and plasma of healthy subjects, respectively, and only 58% in plasma of hemodialyzed patients.
Additional Keyphrases: cancer hemodlalysis patients
Lipid peroxidation, a general mechanism of tissue damage by free radicals, is known to be responsible for cell damage and may induce pathological events (1). Clinical chemistry tests to assess lipid peroxidation include the following techniques: fluorometry of lipofuscin-like substances in serum (2) ; spectrophotometry of conjugated dienes in lipid extracts of plasma and microsomes (3, 4); gas chromatography of ethane or pen-tane in exhaled breath (5) ; hydroperoxide determination (6); malondialdehyde (MDA) evaluation with or without thiobarbituric acid (TBA) reaction and spectrophotometry (7), fluorometry (8), and high-performance liqwd (HPLC) (9, 10) or gas-liquid (11, 12) chromatographies; measurements of other saturated and unsaturated aldehydes (13) ; and oxygen uptake during lipid peroxidation (14) .
The most widely used method is the TBA reaction with MDA. This method is of particular interest because of its procedural simplicity and nanomolar sensitivity. However, the method lacks specificity, as pointed out by several authors (10) (11) (12) (13) (14) (15) (16) , and often leads to overestimation of MDA concentrations (17) .
On the other hand, in biological samples, MDA may exist both in free and in hydrolyzable bound forms involving primary amino groups of proteins, nucleic acids, and other biological nucleophiles. Moreover, MDA may be liberated by acid hydrolysis or metalcatalyzed thermal decomposition from lipoperoxide precursors (18) (19) (20) and from adducts with amino groups (21) . MDA may also be induced by incubation with ascorbate and iron/adenosinediphosphate (22,23), with a hypoxanthine/xanthine oxidase system (24), with NADPH (25) , or with xenobiotics such as Cd4 (26) ,
paraquat (27, 28) , or adriamycin (29) . Indeed, the MDA amount measured varies greatly according to the different experimental conditions (7, 19, (30) (31) (32) and it is difficult to assess whether the MDA value correlates well with in vivo peroxidations. For these reasons, many papers report various methods for forming the MDA/ TBA adduct, which leads to some difficulties in interpreting the results.
Direct HPLC determinations in human plasma did not detect free MDA on an amino phase column, as published by Largilli#{232}re and Melancon (33) , even though the lower limitof detection of their method was 0.48 zmol/L. Moreover, direct HPLC determination of MBA was not applicable to whole blood and serum or plasma, which contain several interfering compounds that co-eluted with MBA on the amino phase column In this paper we describe the best conditions of bloodsample preparation including acid or basic treatments, with subsequent TBA reaction and analyses by HPLC. The MDAIFBA adduct is eluted from octadecyl silica gel columns by the methanol/phosphate buffer method of Wong et al. (19) , slightly modified to improve the technical conditions.
We have used this modified method to determine serum and plasma values of MDA in healthy subjects and patients with high risk of lipoperoxidation.
Materials and Methods

HPLC Apparatus
Analytical HPLC separations were performed with a Model 510 liquid chromatograph ( The TEP stock solution, stored at 4#{176}C, was stable for one month, whereas the working standard solutions had to be prepared every day.
Free MDA and sodium MDA were prepared from TEP as described previously (34, 35) .
Buffers: Potassium phosphate buffer was 50 mmol/L, with pH 5.8-6.8. Stock solutions were prepared by dissolving, per liter, 31.2 g of Na2HPO4 . 2H20(solution A) and 71.7 g of Na2HPO4' 12H20 (solution B). Phosphate buffer was obtained by mixing x mL of A with y mL of B and diluting up to a total of 400 mL as described by Gomori (37) ; pH values were monitored with a pH meter (Qu#{233}r#{233}, Bordeaux, France). Potassium phosphate buffers of pH 5.8, but varying from 10 to 50 mmol/L, were prepared by mixing the stock solutions as described above and diluting them to yield the required concentration.
HPLC eluting solution was prepared daily by mixing 400 niL of distilled methanol with 600 mL of phosphate buffer (19) . Just before use, the mobile phase was filtered through a Millipore membrane GV 0.45 pm (Waters), and degassed under reduced pressure. conditions, the mean pH value of the samples we analyzed was 0.75 ± 0.07 (mean ± SD). We selected a pH <1 tominimize TEAreaction with oxidized compounds, other than MBA (7) , because the reaction with pure MDA is not pH dependent (39 (37) , containing various amounts (0.2-8.7 mmol/L) of MBA as the sodium enol salt (35) . After precipitating the protein with an equal volume of absolute ethanol (41), we centrifuged the samples at 1000 x g for 10 mm. We washed the residue four times, each with 10 mL of distilled water, and then added 10 mL of distilled water to the residue. Finally, we treated 1-mL aliquots of The MBAITBA chromogen isolated by HPLC procedure on a Nucleosil 5 C18 semi-preparative column, with a flow rate of 1.8 mLlmin, was concentrated under reduced pressure at 50#{176}C, then was scanned with a Secoman S1000 spectrophotometer (Secoman, Sarcelles, France). We then analyzed the product by "high-performance" thin-layer chromatography (HP'l'LC) on a 0.5-mm-thick plate of Silica gel G (Merck, Darmstadt, F.R.G.). An aliquot containing about 0.75 pg of MDAJTBA chromogen was applied in a 0.8-cm band to the plate, which we developed with chloroformimethanol/water (65/25/4, by vol) as the mobile phase. The developed plate was dried at room temperature and the naturally colored spot was stabilized by spraying it with a saturated solution of TEAin 300 g/L acetic acid and heating the plate at 100 #{176}C for 10 miii (41). The plate was then scanned with a Camag TLC scanner 76510 (Camag, Muttenz, Switserland) in the reflectance mode at 546 and at 254 nm, coupled with an SP 4100 integrator (Spectra-Physics,Lea Ulis,
Procedures
Statistics: Student's t-test was used for calculating the statistical significance of the data.
Results
Optimizingthe HPLC Procedure
Optimal conditions for separating the MDA,TBA adduct were evaluated by varying the pH or the concentration of the phosphate buffer (from pH 6.8 to 5.8 and from 50 to 10 mmol/L). The proportion of phosphate buffer and methanol (60/40 by vol) in the eluting solution was similar to that used in the HPLC technique of Wong et al. (19) . Three different columns were also tested. The decrease in phosphate buffer concentrations, from 50 to 10 mmol/L, in the mobile phase did not affect the narrow symmetrical shape of the MBA!FBApeak, although retention times were modified. However, omitting the phosphate buffer from the mobile phase resulted in a poor separation from interfering peaks. ration. Using these specified conditions, we performed the subsequent analyses without regard as to whether Bondex or pBondapak C18columns were used, as described previously.
The standard curve generated from the action of TEA on TEP, at the pH of the blood-sample preparations, gave a linear response between MDAITBA concentrations (x) and HPLC peak areas (y): y = 17.06x + 24.26 (r = 0.848; P <0.01). MBAPFBAconcentrations were checked by measuring the absorbance in 1-cm-pathlength cuvets at 532 nm; the recorded peak areas were electronically integrated.
Under these conditions, we estimated 1.1 pmol per ujection (corresponding to a blood concentration of 0.05 pznol/L) to be the lower limit of detection of the method.
Application to free and total MDA determination of blood samples: We used this method to determine MBA in hrnnstn blood samples treated under either acidic (free MBA) or basic conditions (free plus bound MBA). Blood samples were obtained from healthy subjects and from two groups of patients with high risk of increase in MBA concentration due to cancer or hemodialysis. Free and total MBA were measured in serum and plasma by HPLC. The MDAI'FBA chromogen peak in serum or plasma, identified by comparing its HPLC retention time with that of authentic MBA standard, was collected separately, concentrated, and scanned spectrephotometrically from 400 to 650 nm. This spectral profile was identical to that of the authentic standard ( Figure 1 ). The MBAPFBAchromogen purified by preparative HPLC was analyzed by the HPLC procedure described previously and gave a single peak. HPTLC results of the purified chromogen are illustrated in Figure 2 .The sample yielded a major TEA-reactive spot at R = 0.53 ± 0.07 (mean ± SDfor 10 consecutive runs) and a minor spot, migrating faster, that we consider negligible.
Free MBA results (mean ± SEM) are summarized in Table 1 were also significantly (P <0.001) increased, by 4.9-fold and by 4.1-fold, respectively, in plasma from patients with cancer or undergoing hemodialysis (n = 38). Moreover, in patients with cancer, the free MBA values were slightly higher in serum than in plasma; the same was true for patients being treated with hemodialysis (P <0.01, both comparisons).
Total MBA results (mean ± SEM) are shown in Table  2 . The total MBA concentration in sera of healthy persons averaged 0.454 ± 0.066 pmol/L (range 0.155-0.894). We were unable to determine total MBA amounts in serum of patients undergoing hemodialysis because of the presence of large interfering peaks (Figure 3) . Despite filtration on Sep-Pak C18 cartridge (Waters) or on Millex HV (Millipore) and extraction of the MDAITBA adduct with butanol (29) , these sample clean-up procedures did not successfully remove all the interfering substances from the elution profile. The plasma concentration of total MBA in healthy persons averaged 0.429 ± 0.048 nno/L (range 0.100-1.060). The mean total MBA concentration in plasma was not significantly different in patients undergoing hemodialysis (0.645 ± 0.081; range 0.100-1.788).
In (means ± SEM) of total MBA in serum and plasma of healthy subjects, respectively. In patientsundergoing hemodialysis, bound MBA constituted only 58.0% ± 5.6% (mean ± SEM) of total plasma MBA and was significantly lower (P <0.01) than the control value. Blood sample storage: To evaluate the effects of delaying analysis after blood sample collection, we carried out the following studies. Based on our own experience and the low concentration of free MBA in healthy persons, we recommend an immediate preparation of acid extract of serum or plasma for determination of free MBA and storage at -20 #{176}C until the TBA reaction and HPLC analyses. MBA was stable in perchloric acid extraction solvent for at least two weeks at -20 #{176}C before analysis (Table 3 ). Storage at 4#{176}C was unsuitable because MBA seemed to be liberated from its lipoperoxide precursors.
Storage of serum and plasma at -20 #{176}C was suitable for only one week, after which total MBA decreased severely. Moreover, this decrease was more important in serum than in plasma. wanted to determine whether the TBA assay procedure combined with HPLC could be used to obtain qualitatively and quantitatively interpretable results. The TBA reaction is known to have poor specificity, and blood lipoperoxides in particular, or other TBA-reacting substances (TBA-RS), must be eliminated by precipitation, along with blood proteins, by use of perchloric acid (42) . Water-soluble substances (especially MBA) can then be determined by TBA reaction and HPLC analyses.
Discussion
Using the MBAiTBA adduct formation and HPLC analyses, we have detected in serum and plasma of healthy subjectsa low concentration of free MBA: 0.042 ± 0.008 and 0.043 ± 0.007 tmoI/L (mean ± SEM), respectively. We attribute these results to an improved sensitivity of our MDAPFBA-HPLC method in comparison with the direct HPLC method. Moreover, we have collected the MDAPFBA chromogen eluted by HPLC from acidic extract of healthy subjects. Its spectrophotometric proffle is identical to that of authentic standard (Figure 1 )and its HPTLC analysis reveals a major pink component (natural color, without further staining or (Figure 2) and a minor one that we could consider negligible. The scan at 2U ma confirmed that there is no other interfering component. The free MBA value in serum is equal to that in plasma despite platelet aggregation (43) (45) .
We applied our MBA determination method to patients with high risk of increased lipoperoxidation to prove that our procedure is suitable. Under our conditions, free MBA in serum or plasma of patients with various cancers is significantly greater than in healthy subjects ( Table 1) . These results are in contradiction with the low rate of lipid peroxidation observed by severalauthorsin either human (49) or rat (50) tumor cells. However, remember that cells are provided with protective systems against free radical peroxidation damage; in particular, free MBA is readily taken up by cells (51,52).
MBA
is able to combine withproteins and nucleic acids (9, 11, 35) ; it is readily metabolized in vivo by a mitochondrial aldehyde oxidase (53) ; and it is unstable in the presence of hydrogen peroxide (54) . These protector systems may explain the low rate of lipid peroxidation in tumor cells. On the other hand, the activation of phagocytic cells such as macrophages or neutrophils (55) by the occurrence of proliferating cell systems produces free radicals and other oxidative species that could explain the high concentration of free MBA observed in blood. Yet again, it is generally assumed that the natural antioxidants present in blood are sufficient to protect the blood from oxidation (31). These data suggest that the protective systems in blood of patients with various tumor diseases are overcomeby increased radical reactions.
In patients undergoing hemodialysis, we observed a significant increase in free MBA values in serum or plasma (Table 1) ,consistent with an increased oxidative damage as pointed out by Taccone-Galluci et al. in erythrocytes(57) or platelets (58) . Our HPLC analysis of MDA/ TBA adduct was unsuitable for total MBA values in serum from these patients becauseof the presence of large interfering peaks (Figure 3) . Further experiments should allow us to identify these compounds. However, total MBA analyses in plasma have been possibledespite the occurrence of small interfering peaks ( Table 2) . It is interesting to observe, in this case,that total MBA in these subjectsis not significantly different from that in healthy subjects. Thus the present finding demonstrates the interest of making a distinction between free and total MBA.
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